Thorium-227 Anetumab Corixetan: A Pioneering Mesothelin-Targeted Therapeutic for Solid Tumours

Summary: Thorium-227 Anetumab Corixetan (²²⁷Th-BAY2287411) is a groundbreaking mesothelin-targeted thorium conjugate (MSLN-TTC) designed to fight solid tumours that overexpress the mesothelin protein. This innovative agent links a highly specific monoclonal antibody (anetumab) to a potent alpha-emitting radionuclide, thorium-227, via a chelator (3,2-HOPO). The structure of ²²⁷Th-BAY2287411 enables focused delivery of alpha radiation to cancer cells, thereby limiting damage to healthy tissues. Prioritised for ovarian cancer, the therapy has potential applications across multiple tumour types expressing mesothelin. Clinical studies have been conducted to evaluate the safety and efficacy of this novel radiopharmaceutical, and a separate ⁸⁹Zr-labelled tracer has been synthesised for imaging purposes. This article examines the background, mechanism of action, clinical development, and future outlook of Thorium-227 Anetumab Corixetan.

Keywords: Radiopharmaceuticals; Alpha-emitting radionuclides; Mesothelin; Thorium-227; Targeted therapy; Ovarian cancer.

Introduction to Targeted Therapies

Over the past few decades, the field of oncology has witnessed significant advances in targeted therapies that promise more precise treatment modalities with fewer systemic side effects. One area of promising development is the utilisation of alpha-emitting radionuclides to kill cancer cells, particularly when combined with antibodies that can selectively bind to tumour cell antigens. Thorium-227 Anetumab Corixetan (²²⁷Th-BAY2287411) exemplifies such an approach. It is a mesothelin-targeted thorium conjugate (MSLN-TTC), meaning it uses an antibody (anetumab) that specifically recognises the mesothelin protein found on certain tumour types, including ovarian cancer, pancreatic cancer, and mesothelioma.

This targeted approach to delivering alpha radiation is especially compelling because alpha particles have a very short range in biological tissue—typically a few cell diameters—yet they possess a high linear energy transfer (LET). This characteristic means they are highly destructive to DNA in their immediate vicinity, limiting off-target effects. The development of thorium-227 as a radionuclide for targeted alpha therapy aligns with ongoing efforts to use radiotherapeutic agents more judiciously, sparing healthy tissue while maximising tumour cell kill rates.

Understanding Mesothelin as a Target

Mesothelin is a cell surface glycoprotein expressed in various cancers, including ovarian carcinoma, pancreatic adenocarcinoma, and malignant pleural mesothelioma. Although its exact physiological role is still under investigation, mesothelin has been implicated in cell adhesion, invasion, and tumour progression. Its overexpression in cancer cells, combined with limited expression in normal tissues, makes mesothelin an attractive target for antibody-mediated therapies.

Role of Mesothelin in Cancer:

• Mesothelin appears to aid in tumour growth and metastasis by facilitating interactions between tumour cells and the surrounding stromal environment.
• High levels of mesothelin are associated with more aggressive disease and poorer prognoses, reinforcing the rationale to target it therapeutically.

Advantages of Mesothelin as a Target:

• It has limited expression in healthy tissues, which can reduce off-target toxicity.
• It is present in multiple tumour types, so therapies that target mesothelin can have broader applications.

Given these characteristics, mesothelin is a logical candidate for antibody-based therapeutics and diagnostic tools. Several mesothelin-targeted agents are currently under development or in clinical trials, highlighting the importance and versatility of this target across various oncological indications.

The Science Behind Thorium-227 Anetumab Corixetan

Thorium-227 Anetumab Corixetan (²²⁷Th-BAY2287411) is composed of three main components:

• Anetumab is a human immunoglobulin G1 (IgG1) monoclonal antibody.
• A chelator moiety (3,2-HOPO), which binds thorium-227 with high affinity.
• The radionuclide thorium-227 is an alpha emitter that delivers potent cytotoxic radiation to tumour cells.

Anetumab

Anetumab is an antibody specifically designed to bind to the mesothelin protein. By engineering the antibody to exhibit a high affinity for mesothelin, researchers have optimised its ability to target and recognise tumour cells selectively. This selectivity is critical for minimising damage to healthy tissues.

Chelator (3,2-HOPO)

Linking a radioactive metal to a monoclonal antibody poses challenges, as the radionuclide must remain stably attached to the antibody during circulation in the bloodstream to maximise tumour targeting. The chelator 3,2-HOPO (3-hydroxypyridin-2-one) has proven to be effective for binding thorium-227. Its robust complexation chemistry ensures that the radionuclide remains attached to the antibody until it reaches the tumour site.

Alpha-Emitting Nuclide: Thorium-227

Thorium-227 is chosen for its alpha-emitting properties, which are uniquely suited for oncology applications because of the short path length and high energy of alpha particles. This results in:

• High localised cytotoxicity at the site of the tumour.
• Minimal off-target irradiation of surrounding healthy tissue.

Once the antibody binds to mesothelin-expressing tumour cells, the thorium-227 delivers lethal doses of alpha radiation directly to those cells, causing irreparable DNA damage and subsequent cell death.

Mechanism of Action and Radiobiology

Radiopharmaceuticals such as Thorium-227 Anetumab Corixetan capitalise on the dual selectivity of an antibody-based approach and the potency of alpha particle radiation. When administered intravenously, the conjugate circulates through the body until it encounters cells expressing mesothelin. The following steps summarise its mechanism of action:

• Selective Binding: The anetumab portion recognises and binds to mesothelin on the surface of tumour cells.
• Internalisation: Upon binding, the antibody-antigen complex may be internalised via endocytosis or remain on the cell surface. In either case, the proximity of thorium-227 to the tumour cell’s nucleus ensures maximum damage.
• Alpha Particle Emission: Thorium-227 undergoes radioactive decay, releasing alpha particles. These high-LET particles induce DNA double-strand breaks and other forms of damage.
• Tumour Cell Death: The accumulation of DNA damage triggers cell death mechanisms such as apoptosis, reducing the ability of tumour cells to replicate and spread.

The efficacy of alpha-emitting agents stems from their high linear energy transfer. Even a few alpha particle tracks can cause lethal DNA damage, making them especially powerful against resistant tumour populations that may not respond well to conventional therapies such as chemotherapy and external beam radiation.

Therapeutic Applications and Clinical Trials

Ovarian cancer is a challenging disease often diagnosed in advanced stages. It is frequently characterised by elevated levels of mesothelin, making it an ideal target for Thorium-227 Anetumab Corixetan. Standard treatments involve surgery and chemotherapy, though recurrent disease remains a major obstacle. Targeted alpha therapy offers a novel approach that can specifically attack residual tumour cells, potentially improving outcomes.

Other Potential Indications

Mesothelin is expressed in other solid tumours, including pancreatic cancer and malignant pleural mesothelioma. These malignancies also have limited treatment options. Consequently, if Thorium-227 Anetumab Corixetan proves safe and effective in clinical trials, it could be broadened to treat multiple cancer types that overexpress mesothelin.

Clinical Development

A clinical study of Thorium-227 BAY2287411 was initiated in patients whose tumours are known to express mesothelin. This study aimed to evaluate the radiopharmaceutical’s safety, tolerability, and preliminary efficacy. Completed in March 2022, the trial provided valuable data on the pharmacokinetics, biodistribution, and potential adverse effects of ²²⁷Th-BAY2287411.

• Safety Profile: Researchers closely monitored blood counts, liver function, and kidney function. As alpha emitters can lead to bone marrow suppression, continuous assessment of toxicity was crucial.
• Efficacy Signals: Investigators looked for tumour shrinkage, stabilisation of disease, or other biomarkers indicative of therapeutic response.
• Biomarker Studies: In parallel, tissue and blood samples were analysed to confirm mesothelin expression and to correlate expression levels with response rates.

Although detailed results have yet to be fully reported in peer-reviewed publications, preliminary indications suggest that Thorium-227 Anetumab Corixetan has an acceptable safety profile and warrants further study. Additional trials, possibly including Phase II or combination studies with chemotherapy or immunotherapy, may follow.

Synthesis of the ⁸⁹Zr-Labelled Tracer

An essential part of developing targeted radiopharmaceuticals is accurately gauging their distribution in the body. For this reason, an imaging analogue of the therapeutic agent has been synthesised using zirconium-89, a positron-emitting radionuclide. This tracer allows for non-invasive imaging with positron emission tomography (PET).

Purpose of the ⁸⁹Zr Tracer

The ⁸⁹Zr-labelled version of the mesothelin-targeting antibody enables clinicians and researchers to:

• Visualise the biodistribution of the agent in real-time.
• Confirm tumour uptake prior to administering the therapeutic version.
• Optimise dosing regimens by evaluating how quickly and effectively the antibody accumulates in the tumour.

Production and Characteristics

Zirconium-89 is produced via cyclotron irradiation and then complexed with a suitable chelator to form a stable compound with the mesothelin-targeting antibody. Similar to the therapeutic conjugate, stability in circulation is paramount to ensure minimal release of radioactive species into healthy tissues. The imaging scans that follow administration of the tracer can offer insights into tumour targeting, helping clinicians to make data-driven decisions on patient selection and dosing strategies.

Future Outlook for Thorium-227 Anetumab Corixetan

The development of Thorium-227 Anetumab Corixetan signifies a broader trend in nuclear medicine, wherein alpha-emitting radionuclides are increasingly explored for their potent cytotoxic effects and ability to overcome resistance to traditional therapies. Several avenues are of interest:

Combination Therapies: Thorium-227 Anetumab Corixetan may work synergistically with conventional chemotherapy or immune checkpoint inhibitors. By combining treatments, physicians could exploit multiple vulnerabilities in tumour cells, potentially enhancing overall therapeutic response.

Precision Medicine Approaches: As companion diagnostics become more sophisticated, selecting patients with the highest mesothelin expression or particular genomic signatures can help maximise therapeutic benefit while reducing unnecessary exposure to radiation.

Expansion to Other Targets and Radionuclides: The success of ²²⁷Th-BAY2287411 may pave the way for the development of other thorium-based conjugates targeting different tumour antigens. Additionally, investigators may explore other alpha emitters, such as radium-223 or actinium-225, for different clinical scenarios.

Long-Term Safety and Secondary Cancers: While alpha therapy has great promise, continuous monitoring is necessary to assess long-term toxicity, including the risk of secondary malignancies. Rigorous follow-up of patients in clinical trials will be crucial to establish a solid safety profile.

• Commercialisation and Accessibility: As radiopharmaceuticals become more widely adopted, issues related to manufacturing scale-up, distribution, and cost will influence their accessibility. Regulatory bodies will scrutinise clinical data for evidence of safety and efficacy, and reimbursement frameworks will need to accommodate these novel therapies.

Conclusion

Thorium-227 Anetumab Corixetan represents a novel approach to managing mesothelin-expressing tumours by uniting targeted antibody therapy with the potent cytotoxic effect of alpha-emitting radiation. The agent’s design capitalises on anetumab’s specificity for mesothelin, a chelator that secures thorium-227 tightly, and alpha particles that inflict highly localised damage to tumour cells. Ovarian cancer, characterised by poor prognosis and mesothelin overexpression, is an early priority for this therapy, though its potential extends to other cancers where mesothelin is implicated.

The recent clinical study completed in March 2022 provides initial insights into the safety and tolerability of ²²⁷Th-BAY2287411, and future trials will further elucidate efficacy and optimal use in combination with other therapies. The companion ⁸⁹Zr-labelled tracer likewise enables clinicians to image and quantify the drug’s biodistribution, allowing for fine-tuning of dosage and patient selection.

Notwithstanding the challenges that come with bringing a targeted alpha therapy from bench to bedside—such as complex manufacturing, the need for robust clinical data, and concerns about long-term toxicity—Thorium-227 Anetumab Corixetan stands at the forefront of a promising category of radiopharmaceuticals. The ultimate goal is to harness the power of alpha particles to deliver precise, effective, and tolerable cancer treatment that could significantly improve outcomes for patients with otherwise limited treatment options.

By advancing the science of targeted alpha therapy and pushing the boundaries of antibody-based cancer interventions, Thorium-227 Anetumab Corixetan may herald a new era in oncology—one in which highly targeted, potent radionuclide treatments deliver meaningful clinical benefits while preserving the quality of life for patients. Through ongoing research, meticulous clinical testing, and supportive regulatory pathways, this innovative agent holds the potential to make a substantial impact in the fight against some of the most challenging solid tumours in modern medicine.

You are here: home » Thorium-227 Anetumab Corixetan